US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Bicara Therapeutics

15.36

+0.26001.72%

Post-market: 15.28-0.0800-0.52%18:03 EST

Volume:405.52K

Turnover:6.23M

Market Cap:841.45M

PE:-6.90

High:16.00

Open:15.53

Low:14.90

Close:15.10

52wk High:19.71

52wk Low:7.80

Shares:54.78M

Float Shares:24.13M

Volume Ratio:1.15

T/O Rate:1.68%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2271

EPS(LYR):-4.0460

ROE:-26.64%

ROA:-18.59%

PB:2.09

PE(LYR):-3.80

Loading ...

Overview Company News Filings

Bicara Therapeutics announces inducement grants

Bicara Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics Initiated at Market Outperform by Citizens

Bicara Therapeutics CFO Ivan Hyep Reports Disposal of Common Shares

Bicara Therapeutics President and COO Ryan Cohlhepp Reports Sale of Common Shares

BCAX: De-Risked FORTIFI-HN01 Path, Differentiated Ficera Profile, and Solid Cash Runway Underpin Buy Rating and $28 Target

Wedbush Reaffirms Their Buy Rating on Bicara Therapeutics Inc. (BCAX)

Bicara Therapeutics Price Target Maintained With a $30.00/Share by Wedbush

Bicara Therapeutics unveils pipeline advances for FICERA in HPV-negative head and neck cancer

BRIEF-Bicara Therapeutics Announces Phase 3 Optimal Dose And Provides 2026 Corporate Outlook

Bicara Therapeutics Inc - Anticipates Multiple Data Readouts in 2026 for Ficerafusp Alfa

THOMSON REUTERS

Bicara Therapeutics - Expects to Achieve Substantial Enrollment in Fortifi-Hn01 in 2026 to Enable Interim Analysis in Mid-2027

THOMSON REUTERS

Bicara Therapeutics Initiated at Buy by BTIG

Bicara Therapeutics Inc : Btig Initiates Coverage With Buy Rating; Target Price $28

THOMSON REUTERS

BTIG Research Initiates Coverage on Bicara Therapeutics With Buy Rating, $28 Price Target

MT Newswires Live

Bicara Therapeutics CFO Ivan Hyep Reports Disposal of Common Shares

U.S. RESEARCH ROUNDUP-Autozone, Coursera, Lennar

President and COO Ryan Cohlhepp Reports Disposal of Bicara Therapeutics Inc. Common Shares

How Breakthrough Status For Ficerafusp Combo At Bicara Therapeutics (BCAX) Has Changed Its Investment Story

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BCAX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCAX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":15.36,"timestamp":1770411600000,"preClose":15.1,"halted":0,"volume":405522,"hourTrading":{"tag":"盘后","latestPrice":15.28,"preClose":15.36,"latestTime":"18:03 EST","volume":18022,"amount":276221.76,"timestamp":1770419000617,"change":-0.08,"changeRate":-0.005208,"amplitude":0.026693},"delay":0,"changeRate":0.0172185430463576,"floatShares":24134001,"shares":54781950,"eps":-2.227112,"marketStatus":"Market Closed","change":0.26,"latestTime":"02-06 16:00:00 EST","open":15.53,"high":16.0026,"low":14.895,"amount":6227289.5075819995,"amplitude":0.073351,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.227112,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":15.1,"postHourTrading":{"tag":"盘后","latestPrice":15.28,"preClose":15.36,"latestTime":"18:03 EST","volume":18022,"amount":276221.76,"timestamp":1770419000617,"change":-0.08,"changeRate":-0.005208,"amplitude":0.026693},"volumeRatio":1.1533421341654353,"impliedVol":0.626,"impliedVolPercentile":0.753},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","floatShares":24134001,"roa":"-18.59%","roe":"-26.64%","lyrEps":-4.045991,"volumeRatio":1.1533421341654353,"shares":54781950,"dividePrice":0,"high":16.0026,"amplitude":0.073351,"preClose":15.1,"low":14.895,"week52Low":7.8,"pbRate":"2.09","week52High":19.71,"institutionHeld":0,"latestPrice":15.36,"eps":-2.227112,"divideRate":0,"volume":405522,"delay":0,"ttmEps":-2.227112,"open":15.53,"prevYearClose":16.83,"prevWeekClose":16.8,"prevMonthClose":16.8,"prevQuarterClose":16.83},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCAX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-10","symbol":"BCAX","fiscalQuarterEnding":"2025/09","expectedEps":-0.55,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2025-08-12","symbol":"BCAX","fiscalQuarterEnding":"2025/06","expectedEps":-0.54,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-0.5},{"market":"US","date":"2025-05-13","symbol":"BCAX","fiscalQuarterEnding":"2025/03","expectedEps":-0.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-03-27","symbol":"BCAX","fiscalQuarterEnding":"2024/12","expectedEps":-0.31,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"pre","actualEps":-0.39},{"market":"US","date":"2024-11-12","symbol":"BCAX","fiscalQuarterEnding":"2024/09","expectedEps":-0.46,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.6}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCAX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCAX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5833,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5833,"analysts":12,"updateTime":1769749200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCAX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCAX","date":"2026-02-05","current":-6.896824,"percent":0.713467,"low":-22.704836,"twenty":-15.936393,"median":-9.049024,"eighty":-6.555923,"high":-5.144536,"avg":-10.770753,"sd":4.745771,"marketCap":896780521},"quantilePoints":[{"date":"2024-09-13","current":-12.837909,"twenty":-12.837909,"median":-12.837909,"eighty":-12.837909,"marketCap":832435719},{"date":"2024-09-20","current":-20.633135,"twenty":-21.391361,"median":-20.283845,"eighty":-14.007791,"marketCap":1337893755},{"date":"2024-09-27","current":-21.555755,"twenty":-21.594337,"median":-21.446718,"eighty":-19.006626,"marketCap":1397718272},{"date":"2024-10-04","current":-19.962139,"twenty":-21.575885,"median":-21.337681,"eighty":-19.559541,"marketCap":1294385015},{"date":"2024-10-11","current":-15.936161,"twenty":-21.540658,"median":-20.570229,"eighty":-18.732598,"marketCap":1033332575},{"date":"2024-10-18","current":-17.143955,"twenty":-21.466848,"median":-20.283845,"eighty":-16.808457,"marketCap":1111648307},{"date":"2024-10-25","current":-18.964032,"twenty":-21.403103,"median":-19.23243,"eighty":-16.959431,"marketCap":1229665764},{"date":"2024-10-31","current":-19.878264,"twenty":-21.362844,"median":-19.23243,"eighty":-17.02653,"marketCap":1288946422},{"date":"2024-11-08","current":-19.79439,"twenty":-21.337681,"median":-19.82794,"eighty":-17.143955,"marketCap":1283507830},{"date":"2024-11-15","current":-20.345116,"twenty":-21.127995,"median":-19.949558,"eighty":-18.418848,"marketCap":1210086831},{"date":"2024-11-22","current":-16.257533,"twenty":-21.102833,"median":-19.82794,"eighty":-17.143955,"marketCap":966965549},{"date":"2024-11-29","current":-19.02049,"twenty":-20.975343,"median":-19.458892,"eighty":-17.009755,"marketCap":1131300719},{"date":"2024-12-06","current":-17.876882,"twenty":-20.695202,"median":-19.01323,"eighty":-17.12047,"marketCap":1063281195},{"date":"2024-12-13","current":-16.509127,"twenty":-20.532485,"median":-19.005969,"eighty":-17.12047,"marketCap":981929844},{"date":"2024-12-20","current":-15.187116,"twenty":-20.493904,"median":-18.892739,"eighty":-16.769874,"marketCap":903299275},{"date":"2024-12-27","current":-17.49263,"twenty":-20.458153,"median":-18.854995,"eighty":-16.764842,"marketCap":1040426635},{"date":"2025-01-03","current":-15.484454,"twenty":-20.399979,"median":-18.727694,"eighty":-16.641786,"marketCap":920984351},{"date":"2025-01-10","current":-13.952019,"twenty":-20.332862,"median":-18.565256,"eighty":-16.325863,"marketCap":829838189},{"date":"2025-01-17","current":-10.868852,"twenty":-20.271506,"median":-18.306879,"eighty":-15.951961,"marketCap":646457553},{"date":"2025-01-24","current":-10.951191,"twenty":-20.22215,"median":-18.224539,"eighty":-15.55307,"marketCap":651354959},{"date":"2025-01-31","current":-11.811185,"twenty":-20.138275,"median":-17.666458,"eighty":-14.949245,"marketCap":702505641},{"date":"2025-02-07","current":-11.52757,"twenty":-20.11652,"median":-17.561246,"eighty":-13.156068,"marketCap":685636799},{"date":"2025-02-14","current":-12.003311,"twenty":-19.978914,"median":-17.49263,"eighty":-12.003311,"marketCap":713932921},{"date":"2025-02-21","current":-12.643731,"twenty":-19.965494,"median":-17.085242,"eighty":-11.997822,"marketCap":752023854},{"date":"2025-02-28","current":-11.307997,"twenty":-19.942009,"median":-16.815614,"eighty":-11.891694,"marketCap":672577050},{"date":"2025-03-07","current":-14.409462,"twenty":-19.890007,"median":-16.73236,"eighty":-11.891694,"marketCap":857045999},{"date":"2025-03-14","current":-12.213735,"twenty":-19.838005,"median":-16.60519,"eighty":-11.893524,"marketCap":726448513},{"date":"2025-03-21","current":-11.975864,"twenty":-19.8011,"median":-16.394587,"eighty":-11.882546,"marketCap":712300452},{"date":"2025-03-28","current":-10.745093,"twenty":-19.525992,"median":-16.092853,"eighty":-11.882546,"marketCap":730612568},{"date":"2025-04-04","current":-9.486153,"twenty":-19.364339,"median":-15.936742,"eighty":-11.721526,"marketCap":645010946},{"date":"2025-04-11","current":-8.139007,"twenty":-19.311424,"median":-15.55307,"eighty":-11.500123,"marketCap":553411758},{"date":"2025-04-17","current":-9.430022,"twenty":-19.133936,"median":-15.269456,"eighty":-11.355571,"marketCap":641194313},{"date":"2025-04-25","current":-12.533268,"twenty":-19.02049,"median":-15.045308,"eighty":-11.297018,"marketCap":852199585},{"date":"2025-05-02","current":-11.795546,"twenty":-19.011777,"median":-14.409462,"eighty":-11.329955,"marketCap":802038125},{"date":"2025-05-09","current":-10.531076,"twenty":-18.980807,"median":-14.002338,"eighty":-11.242349,"marketCap":716060542},{"date":"2025-05-16","current":-8.546663,"twenty":-18.933837,"median":-13.265854,"eighty":-11.091295,"marketCap":789139074},{"date":"2025-05-23","current":-9.249533,"twenty":-18.888545,"median":-12.837909,"eighty":-10.95668,"marketCap":854037173},{"date":"2025-05-30","current":-5.575709,"twenty":-18.86506,"median":-12.634583,"eighty":-10.80298,"marketCap":514821897},{"date":"2025-06-06","current":-6.514837,"twenty":-18.854995,"median":-12.506498,"eighty":-10.643069,"marketCap":601534484},{"date":"2025-06-13","current":-6.833787,"twenty":-18.81138,"median":-12.341819,"eighty":-10.421008,"marketCap":630984042},{"date":"2025-06-20","current":-5.569802,"twenty":-18.738652,"median":-12.190862,"eighty":-10.145292,"marketCap":514276535},{"date":"2025-06-27","current":-5.203601,"twenty":-18.705007,"median":-12.094799,"eighty":-9.441248,"marketCap":480464080},{"date":"2025-07-03","current":-5.333543,"twenty":-18.687321,"median":-12.003311,"eighty":-9.12531,"marketCap":492462048},{"date":"2025-07-11","current":-5.859219,"twenty":-18.443191,"median":-11.975864,"eighty":-8.617541,"marketCap":540999282},{"date":"2025-07-18","current":-6.881039,"twenty":-18.418848,"median":-11.920971,"eighty":-8.339475,"marketCap":635346939},{"date":"2025-07-25","current":-7.04642,"twenty":-18.306879,"median":-11.898098,"eighty":-7.625808,"marketCap":650617080},{"date":"2025-08-01","current":-6.562089,"twenty":-18.251986,"median":-11.884376,"eighty":-7.016887,"marketCap":605897381},{"date":"2025-08-08","current":-6.0246,"twenty":-18.224539,"median":-11.847781,"eighty":-6.881039,"marketCap":556269423},{"date":"2025-08-15","current":-6.063601,"twenty":-17.876882,"median":-11.795546,"eighty":-6.786535,"marketCap":622562015},{"date":"2025-08-22","current":-6.180515,"twenty":-17.675607,"median":-11.648291,"eighty":-6.638873,"marketCap":634565840},{"date":"2025-08-29","current":-6.329315,"twenty":-17.657309,"median":-11.619058,"eighty":-6.514837,"marketCap":649843436},{"date":"2025-09-05","current":-6.409029,"twenty":-17.584119,"median":-11.52757,"eighty":-6.407746,"marketCap":658027862},{"date":"2025-09-12","current":-6.366515,"twenty":-17.562161,"median":-11.3858,"eighty":-6.401771,"marketCap":653662835},{"date":"2025-09-19","current":-5.877601,"twenty":-17.506353,"median":-11.36289,"eighty":-6.371769,"marketCap":603465021},{"date":"2025-09-26","current":-5.686286,"twenty":-17.49263,"median":-11.294273,"eighty":-6.328252,"marketCap":583822398},{"date":"2025-10-03","current":-8.880173,"twenty":-17.49263,"median":-11.226216,"eighty":-6.328252,"marketCap":911745073},{"date":"2025-10-10","current":-9.712715,"twenty":-17.21369,"median":-11.089726,"eighty":-6.337818,"marketCap":997223830},{"date":"2025-10-17","current":-9.936118,"twenty":-17.050015,"median":-11.051829,"eighty":-6.344195,"marketCap":1020161070},{"date":"2025-10-24","current":-8.999952,"twenty":-16.959431,"median":-10.928319,"eighty":-6.362264,"marketCap":924043110},{"date":"2025-10-31","current":-8.755273,"twenty":-16.841022,"median":-10.759065,"eighty":-6.371769,"marketCap":898921371},{"date":"2025-11-07","current":-7.749959,"twenty":-16.783048,"median":-10.701761,"eighty":-6.376332,"marketCap":795703789},{"date":"2025-11-14","current":-6.428441,"twenty":-16.754777,"median":-10.617258,"eighty":-6.376332,"marketCap":781190607},{"date":"2025-11-21","current":-7.293982,"twenty":-16.72193,"median":-10.425573,"eighty":-6.385646,"marketCap":886371951},{"date":"2025-11-28","current":-8.366891,"twenty":-16.703998,"median":-10.156917,"eighty":-6.394149,"marketCap":1016752992},{"date":"2025-12-05","current":-8.457052,"twenty":-16.641786,"median":-10.005266,"eighty":-6.400929,"marketCap":1027709382},{"date":"2025-12-12","current":-8.497624,"twenty":-16.572254,"median":-9.798232,"eighty":-6.406463,"marketCap":1032639757},{"date":"2025-12-19","current":-7.952153,"twenty":-16.525595,"median":-9.707395,"eighty":-6.409029,"marketCap":966353598},{"date":"2025-12-26","current":-7.785356,"twenty":-16.417495,"median":-9.581658,"eighty":-6.416794,"marketCap":946084276},{"date":"2026-01-02","current":-7.587003,"twenty":-16.275544,"median":-9.536519,"eighty":-6.433907,"marketCap":921980218},{"date":"2026-01-09","current":-7.465287,"twenty":-16.224597,"median":-9.44371,"eighty":-6.465223,"marketCap":907189092},{"date":"2026-01-16","current":-7.523891,"twenty":-16.076385,"median":-9.207398,"eighty":-6.505387,"marketCap":914310745},{"date":"2026-01-23","current":-7.929613,"twenty":-16.010514,"median":-9.12531,"eighty":-6.514837,"marketCap":963614500},{"date":"2026-01-30","current":-7.623067,"twenty":-15.937323,"median":-9.082399,"eighty":-6.531258,"marketCap":926362774},{"date":"2026-02-05","current":-7.379634,"twenty":-15.936393,"median":-9.049024,"eighty":-6.555923,"marketCap":896780521}],"updateTime":1770447092092},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCAX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609305637","title":"Bicara Therapeutics announces inducement grants","url":"https://stock-news.laohu8.com/highlight/detail?id=2609305637","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609305637?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:41","pubTimestamp":1770298895,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) awarded inducement grants on February 2, 2026 to two new employees under Bicara’s 2026 Inducement Plan as a material ind...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-announces-inducement-grants-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-announces-inducement-grants-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2609730343","title":"Bicara Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2609730343","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609730343?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:30","pubTimestamp":1770298203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nTUA3H5LF7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2609037493","title":"Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2609037493","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609037493?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:30","pubTimestamp":1770298200,"startTime":"0","endTime":"0","summary":"BOSTON, Feb.  05, 2026  (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/05/3232983/0/en/Bicara-Therapeutics-Announces-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2607595033","title":"Bicara Therapeutics Initiated at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2607595033","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607595033?lang=en_us&edition=fundamental","pubTime":"2026-01-29 22:10","pubTimestamp":1769695800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 29, 2026 09:10 ET (14:10 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX"],"gpt_icon":0},{"id":"2606229806","title":"Bicara Therapeutics CFO Ivan Hyep Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2606229806","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606229806?lang=en_us&edition=fundamental","pubTime":"2026-01-27 05:34","pubTimestamp":1769463261,"startTime":"0","endTime":"0","summary":"Ivan Hyep, Chief Financial Officer of Bicara Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 26, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDLb33MZc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara Therapeutics CFO Ivan Hyep Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2605328144","title":"Bicara Therapeutics President and COO Ryan Cohlhepp Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605328144","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605328144?lang=en_us&edition=fundamental","pubTime":"2026-01-21 05:53","pubTimestamp":1768945997,"startTime":"0","endTime":"0","summary":"Ryan Cohlhepp, President and COO of Bicara Therapeutics Inc., reported a disposal of common shares of Bicara Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL5FkbcK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara Therapeutics President and COO Ryan Cohlhepp Reports Sale of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2604916444","title":"BCAX: De-Risked FORTIFI-HN01 Path, Differentiated Ficera Profile, and Solid Cash Runway Underpin Buy Rating and $28 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2604916444","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604916444?lang=en_us&edition=fundamental","pubTime":"2026-01-17 04:17","pubTimestamp":1768594634,"startTime":"0","endTime":"0","summary":"Analyst Jeet Mukherjee of BTIG reiterated a Buy rating on Bicara Therapeutics Inc., retaining the price target of $28.00. Jeet Mukherjee has given ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/bcax-de-risked-fortifi-hn01-path-differentiated-ficera-profile-and-solid-cash-runway-underpin-buy-rating-and-28-target-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/bcax-de-risked-fortifi-hn01-path-differentiated-ficera-profile-and-solid-cash-runway-underpin-buy-rating-and-28-target-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"2603638916","title":"Wedbush Reaffirms Their Buy Rating on Bicara Therapeutics Inc. (BCAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603638916","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603638916?lang=en_us&edition=fundamental","pubTime":"2026-01-13 22:37","pubTimestamp":1768315050,"startTime":"0","endTime":"0","summary":"In a report released today, from Wedbush maintained a Buy rating on Bicara Therapeutics Inc., with a price target of $30.00. In addition to Wedbush...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-reaffirms-their-buy-rating-on-bicara-therapeutics-inc-bcax-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-reaffirms-their-buy-rating-on-bicara-therapeutics-inc-bcax-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"2603687824","title":"Bicara Therapeutics Price Target Maintained With a $30.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2603687824","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603687824?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:50","pubTimestamp":1768312200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2026 08:50 ET (13:50 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX"],"gpt_icon":0},{"id":"2602510595","title":"Bicara Therapeutics unveils pipeline advances for FICERA in HPV-negative head and neck cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510595","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510595?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:04","pubTimestamp":1768223085,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL6J3n4Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2602851055","title":"BRIEF-Bicara Therapeutics Announces Phase 3 Optimal Dose And Provides 2026 Corporate Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2602851055","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602851055?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:02","pubTimestamp":1768222960,"startTime":"0","endTime":"0","summary":"BRIEF-Bicara Therapeutics Announces Phase 3 Optimal Dose And Provides 2026 Corporate OutlookJan 12 (Reuters) - Bicara Therapeutics Inc BCAX.O:BICARA THERAPEUTICS ANNOUNCES PHASE 3 OPTIMAL DOSE AND PRO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA3TKCWW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2602510369","title":"Bicara Therapeutics Inc - Anticipates Multiple Data Readouts in 2026 for Ficerafusp Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510369","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510369?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222804,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA3TKCWW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2602510367","title":"Bicara Therapeutics - Expects to Achieve Substantial Enrollment in Fortifi-Hn01 in 2026 to Enable Interim Analysis in Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510367","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510367?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA3TKCWW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2601605362","title":"Bicara Therapeutics Initiated at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2601605362","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601605362?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:28","pubTimestamp":1767878880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 08:28 ET (13:28 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2601936901","title":"Bicara Therapeutics Inc : Btig Initiates Coverage With Buy Rating; Target Price $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2601936901","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601936901?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:31","pubTimestamp":1767875497,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y90YO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2601369141","title":"BTIG Research Initiates Coverage on Bicara Therapeutics With Buy Rating, $28 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369141","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369141?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:18","pubTimestamp":1767874704,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) has an average rating of Buy and mean price target of $30.44, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCAX"],"gpt_icon":0},{"id":"2593448761","title":"Bicara Therapeutics CFO Ivan Hyep Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593448761","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593448761?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:03","pubTimestamp":1766523784,"startTime":"0","endTime":"0","summary":"Ivan Hyep, Chief Financial Officer of Bicara Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL7GY46w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara Therapeutics CFO Ivan Hyep Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2592927648","title":"U.S. RESEARCH ROUNDUP-Autozone, Coursera, Lennar","url":"https://stock-news.laohu8.com/highlight/detail?id=2592927648","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592927648?lang=en_us&edition=fundamental","pubTime":"2025-12-18 14:42","pubTimestamp":1766040152,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Autozone, Coursera, LennarDec 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Autozone, Courser","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nL4N3XO0FW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXTA","APD","ARDT","CGNX","AMRZ","BTSG","BRO","ALSN","LU0345769631.USD","COUR","ALB","BSX","BK4090","CL","CF","BIIB","HOUS","BK4548","AZO","BCAX","BK4147","CLW","DG","BBNX","CPT","ASH","CE","DOW","ACAD","BAC","CMI","ACM","CBT","CRL","ACHC","AJG","IE00B7SZLL34.SGD","LU0234570918.USD","BK4107","LU1989763690.USD","SG9999001176.USD","DD","ALL","AAL","CTVA","DAL","AVTX","SGXZ57979304.SGD","CLYM","AMAT"],"gpt_icon":0},{"id":"2592307249","title":"President and COO Ryan Cohlhepp Reports Disposal of Bicara Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592307249","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592307249?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:52","pubTimestamp":1765921958,"startTime":"0","endTime":"0","summary":"Ryan Cohlhepp, President and COO of Bicara Therapeutics Inc., reported a disposal of common shares of Bicara Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 16, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDLbFfP3q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"President and COO Ryan Cohlhepp Reports Disposal of Bicara Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2591672522","title":"How Breakthrough Status For Ficerafusp Combo At Bicara Therapeutics (BCAX) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2591672522","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591672522?lang=en_us&edition=fundamental","pubTime":"2025-12-16 08:36","pubTimestamp":1765845384,"startTime":"0","endTime":"0","summary":"Earlier this month, Bicara Therapeutics reported preliminary Phase 1b data showing that weekly 750 mg ficerafusp alfa plus pembrolizumab was generally well tolerated in first-line HPV-negative recurrent or metastatic head and neck squamous cell carcinoma, and the FDA granted the combination Breakthrough Therapy Designation in this setting.\nNew biomarker findings suggesting stronger TGF-β inhibition and immune activation at the 1,500 mg dose level add scientific weight to Bicara’s ongoing...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcax/bicara-therapeutics/news/how-breakthrough-status-for-ficerafusp-combo-at-bicara-thera","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcax/bicara-therapeutics/news/how-breakthrough-status-for-ficerafusp-combo-at-bicara-thera","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BCAX"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":69,"code":"91000000","status":"200"}]}}